- Home
- RYTM vs PK Comparison
RYTM vs PK Comparison
Compare RYTM & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- PK
- Stock Information
- Founded
- RYTM 2008
- PK 1946
- Country
- RYTM United States
- PK United States
- Employees
- RYTM N/A
- PK N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- PK Real Estate Investment Trusts
- Sector
- RYTM Health Care
- PK Real Estate
- Exchange
- RYTM Nasdaq
- PK Nasdaq
- Market Cap
- RYTM 3.1B
- PK 3.0B
- IPO Year
- RYTM 2017
- PK N/A
- Fundamental
- Price
- RYTM $56.12
- PK $14.86
- Analyst Decision
- RYTM Strong Buy
- PK Buy
- Analyst Count
- RYTM 10
- PK 13
- Target Price
- RYTM $65.80
- PK $18.79
- AVG Volume (30 Days)
- RYTM 552.7K
- PK 3.2M
- Earning Date
- RYTM 11-05-2024
- PK 10-29-2024
- Dividend Yield
- RYTM N/A
- PK 6.73%
- EPS Growth
- RYTM N/A
- PK N/A
- EPS
- RYTM N/A
- PK 1.57
- Revenue
- RYTM $112,530,000.00
- PK $2,662,000,000.00
- Revenue This Year
- RYTM $63.64
- PK N/A
- Revenue Next Year
- RYTM $42.98
- PK $4.04
- P/E Ratio
- RYTM N/A
- PK $9.47
- Revenue Growth
- RYTM 81.55
- PK N/A
- 52 Week Low
- RYTM $35.17
- PK $13.24
- 52 Week High
- RYTM $68.58
- PK $18.05
- Technical
- Relative Strength Index (RSI)
- RYTM 46.95
- PK 45.99
- Support Level
- RYTM $53.39
- PK $14.34
- Resistance Level
- RYTM $57.27
- PK $15.57
- Average True Range (ATR)
- RYTM 2.32
- PK 0.44
- MACD
- RYTM -0.55
- PK -0.15
- Stochastic Oscillator
- RYTM 33.21
- PK 27.25
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 23,428 rooms across 39 hotels in the United States. Park also has interests through joint ventures in another 2,665 rooms in four U.S. hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality U.S. hotels to focus on high-quality assets in domestic gateway markets.